- Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. De Caterina, Raffaele; Ammentorp, Bettina; Darius, Harald; Le Heuzey, Jean-Yves; Renda, Giulia; Schilling, Richard John; Schliephacke, Tessa; Reimitz, Paul-Egbert; Schmitt, Josef; Schober, Christine; Zamorano, José Luis; Kirchhof, Paulus // Heart;Oct2014, Vol. 100 Issue 20, p1625
Purpose Combined oral anticoagulant (OAC) and antiplatelet (AP) therapy is generally discouraged in atrial fibrillation (AF) outside of acute coronary syndromes or stenting because of increased bleeding. We evaluated its frequency and possible reasons in a contemporary European AF population....
- New Guidelines for the Treatment of Atrial Fibrillation. Karpman, Harold L. // Internal Medicine Alert;8/29/2013, Vol. 35 Issue 16, p123
The article presents guidelines for the treatment of atrial fibrillation including information on the treatment for rhythm control, reduction of atrial fibrillation complications, and anticoagulant management for thromboprophylaxis.
- Assess underlying risks when choosing a treatment to prevent strokes in patients with atrial fibrillation. // Drugs & Therapy Perspectives;Jul2011, Vol. 27 Issue 7, p14
Atrial fibrillation is associated with increased risk of stroke. Treatment options to reduce the risk of stroke include antiplatelet agents, anticoagulants and combinations of agents. Treatment decisions should take into consideration the underlying risk of stroke, as well as the risk of bleeding.
- Stroke Prevention: Managing Modifiable Risk Factors. Di Legge, Silvia; Koch, Giacomo; Diomedi, Marina; Stanzione, Paolo; Sallustio, Fabrizio // Stroke Research & Treatment;2012, p1
Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of...
- Guideline provides recommendations to reduce clots after hip, knee replacement. Press, Robert // Orthopedics Today;Nov2011, Vol. 31 Issue 11, p26
The article discusses the updated clinical practice guideline released by the American Academy of Orthopaedic Surgeons Board of Directors, which offers recommendations to reduce venous thromboembolic disease after hip or knee replacement surgery.
- Do Anticoagulants or Antiplatelet Drugs Have a Role in Treating Heart Failure in the Absence of Atrial Fibrillation? Gouda, P; Ezekowitz, J A // Clinical Pharmacology & Therapeutics;Oct2013, Vol. 94 Issue 4, p435
Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients. Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and...
- Management of atrial fibrillation: recommendations from NICE. Wei Yao Lim; Khan, Fakhar // British Journal of Hospital Medicine (17508460);2015, Vol. 76 Issue 7, pC108
The article presents information on the recommendations of the National Institute for Health and Care Excellence on the management of atrial fibrillation (AF) in Great Britain. Topics include how to prevent complications in AF, how antiplatelet therapy is an alternative to aspirin in stroke...
- Clinical. // Nurse Prescribing;Jul2014, Vol. 12 Issue 7, p320
No abstract available.
- PFO Closure for Cryptogenic Stroke? Boyle, Andrew J. // Clinical Cardiology Alert;May2012, Vol. 31 Issue 5, p33
The author discusses a study of optimal medical therapy (OMT) vs. percutaneous device closure of patent foramen ovale (PFO) in patients with cryptogenic stroke or transient ischemic attack (TIA), which concluded that closure with a device did not provide greater benefit than OMT alone for the...